ORCHESTRA BIOMED HOLDINGS IN (OBIO) Forecast, Price Target & Analyst Ratings
NASDAQ:OBIO • US68572M1062
4.305 USD
-0.29 (-6.41%)
Last: Mar 12, 2026, 11:25 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ORCHESTRA BIOMED HOLDINGS IN (OBIO).
Forecast Snapshot
Consensus Price Target
$13.70
+ 218.17% Upside
Next Earnings Forecast
Release DateApr 1, 2026
PeriodQ4 / 2025
EPS Estimate-$0.39
Revenue Estimate943.204K
ChartMill Buy Consensus
81.43%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$13.70
Upside
+ 218.17%
From current price of $4.31 to mean target of $13.70, Based on 14 analyst forecasts
Low
$10.10
Median
$12.24
High
$21.00
Price Target Revisions
1 Month
0.00%
3 Months
0.71%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for OBIO. The average price target is 13.7 USD. This implies a price increase of 218.17% is expected in the next year compared to the current price of 4.305.
The average price target has been revised upward by 0.71% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.43%
OBIO was analyzed by 14 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about OBIO.
In the previous month the buy percentage consensus was at a similar level.
OBIO was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-10 | TD Cowen | Initiate | Buy |
| 2025-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-12 | Barclays | Maintains | Overweight -> Overweight |
| 2025-09-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-20 | BTIG | Downgrade | Buy -> Neutral |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-05 | Barclays | Maintains | Overweight -> Overweight |
| 2025-04-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-20 | BTIG | Initiate | Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-02 | Barclays | Initiate | Overweight |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-22 | HC Wainwright & Co. | Initiate | Buy |
| 2024-07-25 | B. Riley Securities | Initiate | Buy |
| 2024-06-12 | Chardan Capital | Reiterate | Buy -> Buy |
| 2024-03-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-01-19 | Jefferies | Initiate | Buy |
| 2023-08-11 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-08-09 | Chardan Capital | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 1, 2026
PeriodQ4 / 2025
EPS Estimate-$0.39
Revenue Estimate943.204K
Revenue Q2Q272.81%
EPS Q2Q8.06%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
5.73%
EPS (1 Month)
0.00%
EPS (3 Months)
2.38%
Next Earnings Summary
OBIO is expected to report earnings on 4/1/2026. The consensus EPS estimate for the next earnings is -0.39 USD and the consensus revenue estimate is 943.20K USD.
The next earnings revenue estimate has been revised upward by 5.73% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.53M 552.56% | 2.76M -21.81% | 2.638M -4.42% | 3.605M 36.66% | 3.688M 2.30% | 2.809M -23.83% | 23.231M 727.02% | 54.718M 135.54% | 113.54M 107.50% | 146.52M 29.05% | 200.12M 36.58% | 251.02M 25.43% | |
| EBITDA YoY % growth | -32.44M -50.05% | -51.219M -57.89% | -63.993M -24.94% | -75.888M -18.59% | -80.376M -5.91% | -74.868M 6.85% | -78.744M -5.18% | -48.552M 38.34% | 1.938M 103.99% | 44.88M 2,215.79% | 81.702M 82.05% | 113.12M 38.45% | |
| EBIT YoY % growth | -32.66M -49.82% | -51.506M -57.70% | -64.301M -24.84% | -80.228M -24.77% | -88.909M -10.82% | -80.164M 9.84% | -57.446M 28.34% | -22.811M 60.29% | 33.136M 245.27% | 66.147M 99.62% | 117.71M 77.95% | 166.36M 41.33% | |
| Operating Margin | -925.21% | -1,866.16% | -2,437.49% | -2,225.47% | -2,410.76% | -2,853.83% | -247.28% | -41.69% | 29.18% | 45.15% | 58.82% | 66.27% | |
| EPS YoY % growth | N/A | -1.50 84.66% | -1.66 -10.67% | -1.78 -7.43% | -1.63 8.70% | -1.30 20.42% | -0.66 49.22% | -0.19 70.54% | 0.41 314.05% | 0.45 8.19% | 0.83 84.09% | 1.16 40.74% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.39 8.06% | -0.42 13.40% | -0.41 18.81% | -0.40 1.06% | -0.39 -0.91% |
| Revenue Q2Q % growth | 943.204K 272.81% | 887.604K 2.26% | 899.436K 7.59% | 894.948K 3.94% | 911.268K -3.39% |
| EBITDA Q2Q % growth | -19.346M -18.19% | -22.848M -21.29% | -21.318M -11.25% | -21.114M -5.21% | -20.91M -8.08% |
| EBIT Q2Q % growth | -20.578M -23.39% | -22.8M -20.50% | -22.127M -14.49% | -21.765M -7.15% | -21.565M -4.79% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.84%
EPS Next 5 Year
13.50%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-6.00%
Revenue Next 5 Year
74.50%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-4.45%
EBIT Next 5 Year
4.75%
ORCHESTRA BIOMED HOLDINGS IN / OBIO Forecast FAQ
What do analysts expect the price target to be for ORCHESTRA BIOMED HOLDINGS IN (OBIO)?
14 analysts have analysed OBIO and the average price target is 13.7 USD. This implies a price increase of 218.17% is expected in the next year compared to the current price of 4.305.
Can you provide the upcoming earnings date for ORCHESTRA BIOMED HOLDINGS IN?
ORCHESTRA BIOMED HOLDINGS IN (OBIO) will report earnings on 2026-04-01, after the market close.
Can you provide the consensus estimates for ORCHESTRA BIOMED HOLDINGS IN next earnings?
The consensus EPS estimate for the next earnings of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is -0.39 USD and the consensus revenue estimate is 943.20K USD.
What is the consensus rating for ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?
The consensus rating for ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 81.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.